Advertisement

Topics

Latest "Cerus" News Stories

02:18 EDT 23rd July 2018 | BioPortfolio

Here are the most relevant search results for "Cerus" found in our extensive news archives from over 250 global news sources.

More Information about Cerus on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Cerus for you to read. Along with our medical data and news we also list Cerus Clinical Trials, which are updated daily. BioPortfolio also has a large database of Cerus Companies for you to search.

Showing "Cerus" News Articles 1–25 of 31

Thursday 19th July 2018

Cerus to Release Second Quarter 2018 Results on August 2, 2018

Cerus Corporation (Nasdaq:CERS) announced today that its second quarter results will be released on Thursday, August 2, 2018, after the close of the stock market. The company will host a conference call and webcast at 4:15 P.M. EDT that afternoon, during which management will discuss the Company’s financial results and provide a general business overview and ...


Tuesday 10th July 2018

New Navy Policy Implements Full Adoption of Pathogen-Reduced Apheresis Platelets Collected at U.S. Navy Blood Donor Centers

Cerus Corporation (Nasdaq: CERS) announced today that the U.S. Department of the Navy will implement pathogen-reduction for all apheresis platelets collected at Navy Blood Donor Centers. The Bureau of Medicine and Surgery (BUMED) noted that with the recent history with Zika Virus, Ebola, Chikungunya, Dengue, and Babesia, emerging pathogens continu...

Friday 15th June 2018

Cerus Presents Results of European Phase 3 Chronic Anemia Study at the 23rd Congress of European Hematology Association

Cerus Corporation (Nasdaq: CERS) announced that results from SPARC, the Company’s European Phase 3 study evaluating the efficacy and safety of INTERCEPT-treated red blood cells (RBCs) in thalassemia major patients, were presented today at the 23rd Congress of European Hematology Association (EHA) in Stockholm Sweden in a poster presentation entitled, “...


Friday 1st June 2018

Cerus Announces Presentations Highlighting INTERCEPT Blood Systems at the 35th International Congress of the International Society of Blood Transfusion

Cerus Corporation (Nasdaq: CERS) today announced that it will make multiple presentations, including two oral abstracts, that will be featured at the 35th International Congress of the International Society of Blood Transfusion (ISBT) in Toronto, Canada from June 2nd to June 6th, 2018. ISBT is one of the premier congresses in transfusion medicine. ...

Friday 18th May 2018

Cerus gains $15M from contract amendment to support blood transfusion studies

An expanded agreement between HHS' Biomedical Advanced Research and Development Authority and Cerus will provide an additiona -More- 

Wednesday 16th May 2018

Cerus Announces Additional BARDA Funding to Support Development of INTERCEPT Blood System for Red Blood Cells

Amendment provides an incremental $15 million in funding bringing the total potential contract value to more than $200 million Cerus Corporation (Nasdaq: CERS) today announced an amendment to the Company’s contract with the Biomedical Advanced Research and Development Authority (BARDA). The expansion of the agreement provides an additional $15 millio...

Tuesday 8th May 2018

Cerus Corporation Reports First Quarter 2018 Results

Cerus Corporation (Nasdaq:CERS) announced today financial results for the first quarter ended March 31, 2018, and raised its full year guidance for product revenue. First Quarter Highlights and Recent Events First quarter product revenue of $13.6 million Year-over-year Q1 worldwide disposable kit volume up over 100...

Cerus' (CERS) CEO Obi Greenman on Q1 2018 Results - Earnings Call Transcript

Thursday 3rd May 2018

Cerus to Present at the Deutsche Bank 43rd Annual Health Care Conference on Wednesday May 9, 2018

Cerus Corporation (Nasdaq: CERS) announced today that Dr. Laurence M. Corash, co-founder and chief scientific officer, and Lainie Corten, vice president of global marketing, are scheduled to present a corporate update at the Deutsche Bank 43rd Annual Health Care Conference at the InterContinental Hotel Boston on Wednesday, May 9th at 1:30 pm ET. ...

Thursday 26th April 2018

Health Canada approves Cerus’ Intercept blood system for platelets

Cerus announced that Health Canada has approved the commercialization of Intercept blood system for platelets.

Wednesday 25th April 2018

Cerus Announces Health Canada Approval of the INTERCEPT Blood System for Platelets

Cerus Corporation (Nasdaq: CERS) announced today that Health Canada has approved the commercialization of INTERCEPT Blood System for platelets. The INTERCEPT Blood System for platelets is intended for the ex vivo treatment and storage of platelet components. The system is used to inactivate a broad range of pathogens, including viruses, bacteria, and proto...

Cerus to Release First Quarter 2018 Results on May 8, 2018

Cerus Corporation (Nasdaq:CERS) announced today that its first quarter results will be released on Tuesday, May 8, 2018, after the close of the stock market. The company will host a conference call and webcast at 4:15 PM ET that afternoon, during which management will discuss the Company’s financial results and provide a general business overview and out...

Tuesday 24th April 2018

X-Biotix Therapeutics, Inc. Secures $7 million in Series A Financing

Announces Key Additions to Board of Directors and Senior Management X-Biotix Therapeutics, Inc. (X-Biotix), a biotechnology company focused on the discovery and development of novel small molecule antibiotic scaffolds targeting multi-drug-resistant (MDR) Gram-negative pathogens, announced that the company has secured $7 million in a Series A financing ...

Monday 2nd April 2018

Cerus’ RedeS Phase 3 Red Blood Cell Study Expands Into the Continental U.S.

Cerus Corporation (NASDAQ: CERS) announced today that Baylor St. Luke’s Medical Center in Houston became the first center in the continental U.S. to enroll patients in Cerus’ RedeS study. RedeS is a Phase 3 study designed to evaluate the safety and efficacy of INTERCEPT Blood Systems for Red Blood Cells (RBCs) compared to conventional RBCs in regions i...

Saturday 17th March 2018

Cerus Corp CERS Medical Equipment Deals and Alliances Profile [Report Updated: 13022018] Prices from USD $250

SummaryCerus Corp Cerus is a biomedical products company that focuses in the field of blood transfusion safety. It develops and commercializes the INTERCEPT Blood System to enhance blood safety. INTERCEPT Blood System reduces the risk of transfusiontransmitted infections by inactivating a wide range of pathogens including viruses, bacteria and parasites present in donated blood. The product is for...

Friday 16th March 2018

Cerus Corp CERS Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 15022018] Prices from USD $250

SummaryCerus Corp Cerus is a biomedical products company that focuses in the field of blood transfusion safety. It develops and commercializes the INTERCEPT Blood System to enhance blood safety. INTERCEPT Blood System reduces the risk of transfusiontransmitted infections by inactivating a wide range of pathogens including viruses, bacteria and parasites present in donated blood. The product is for...

Tuesday 13th March 2018

Cerus Announces the Fourth Biologics License Application (BLA) Approval for a U.S. Blood Center Customer

Cerus Corporation (NASDAQ: CERS) announced today that The Community Blood Center (CBC) of Appleton, Wisconsin received approval by the U.S. Food and Drug Administration (FDA) on their Biologics License Application (BLA) requesting allowance of interstate distribution of platelets that have been pathogen-reduced with the INTERCEPT Blood System. ...

Thursday 8th March 2018

Cerus' (CERS) CEO Obi Greenman on Q4 2017 Results - Earnings Call Transcript

Cerus Corporation Reports Record Fourth Quarter and Year End 2017 Results

Cerus Corporation (Nasdaq: CERS) today announced financial results for the fourth quarter and year ended December 31, 2017. Recent developments and highlights include: Reported record fourth quarter product revenue of $16.2 million, an increase of 60% compared to the same period in the year prior. Established 201...

Wednesday 7th March 2018

Cerus to Present at the Cowen and Company 38th Annual Health Care Conference on March 13, 2018

Cerus Corporation (NASDAQ: CERS) announced today that William ‘Obi’ Greenman, Cerus’ president and chief executive officer, is scheduled to present a corporate update at the Cowen and Company 38th Annual Health Care Conference at 8:00 am ET on Tuesday, March 13, 2018. A live webcast of the presentation will be available from the Investor Rel...

Tuesday 27th February 2018

Cerus Corporation: Becoming De-Risked With Plenty Of Upside

Thursday 22nd February 2018

Cerus to Release Fourth Quarter and Year End 2017 Results on March 8, 2018

Cerus Corporation (NASDAQ:CERS) announced today that its fourth quarter and year end results for 2017 will be released on Thursday, March 8, 2018, after the close of the stock market. The company will host a conference call and webcast at 4:15 PM ET that afternoon, during which management will discuss the Company’s financial results and provide a general...

Friday 2nd February 2018

Cerus nets $57.2mm through public offering

Cerus Corp. (blood transfusion safety devices) netted $57.2mm through a public sale of 14mm common shares (including the over...

Cerus Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriter’s Option to Purchase Additional Shares

Cerus Corporation (NASDAQ:CERS) today announced the closing of a registered underwritten public offering of its common stock, which included the sale of additional shares of common stock upon full exercise of the underwriter’s option to purchase additional shares. Total proceeds for the offering were $57.5 million, before deducting estimated offering exp...

Cerus nets $49.7mm through public offering

Cerus Corp. (blood transfusion safety devices) netted $49.7mm through a public sale of 12.2mm common shares at $4.10. Proceed...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks